Interactive Session:
140. Direct Acting Antivirals for HCV: State-of-the-Art
Friday, October 19, 2012: 2:00 PM-3:30 PM
Room: Ballroom 20 ABCD
Co-organized with the National Foundation for Infectious Diseases

Learning Objectives:

Cases will cover management and new treatment options for patients with hepatitis C virus (HCV) monoinfection and HIV/HCV coinfection. At the conclusion of this session, participants will be able to:  

  • describe new laboratory modalities for comprehensive patient evaluation
  • discuss treatment options, new drug therapies, and potential side effects
  • describe strategies for coordinating care for patients with advanced liver disease or HIV
  • apply treatment strategies for patient with HCV monoinfection and HIV/HCV coinfection

Challenges specific to patients with HIV will be addressed. The session should be valuable to both experienced and less experienced providers, and will utilize both evidence-based medicine and clinical experiences of the panelists.

Target Audience: Researchers, Public Health Practitioners, Pharmacists, Infectious Diseases Physicians, HIV Specialists, HIV Clinicians, Fellows-in-Training, Fellows, Clinicians, Academicians

Tracks: HIV-STD-TB, Adult ID

Interactive Moderators:  Mark Sulkowski, MD, John Hopkins University School of Medicine and Eliot W. Godofsky, MD, Bach and Godofsky

Presentations:

2:00 PM
State of the Art Lecture
Raymond T. Chung, MD

2:30 PM
Interactive Panelist
Debika Bhattacharya, MD

3:00 PM
Interactive Panelist
David Wyles, MD

3:30 PM
Interactive Panelist
David Thomas, MD, MPH, FIDSA

CME Credits: Maximum of 1.5 hours of AMA PRA Category 1 CreditTM possible

Disclosures:

M. Sulkowski, Abbott: Investigator and Scientific Advisor, Consulting fee and Research support
Boehringer Ingelheim: Investigator and Scientific Advisor, Consulting fee and Research support
Bristol-Myers Squibb: Investigator and Scientific Advisor, Consulting fee and Research support
Gilead Sciences: Investigator and Scientific Advisor, Consulting fee and Research support
Janssen : Investigator and Scientific Advisor, Consulting fee and Research support
Merck : Investigator and Scientific Advisor, Consulting fee and Research support
Novartis : Scientific Advisor, Consulting fee
Roche/Genentech: Investigator and Scientific Advisor, Consulting fee and Research support
Vertex Pharmaceuticals: Investigator and Scientific Advisor, Consulting fee and Research support
Pfizer: Investigator and Scientific Advisor, Consulting fee and Research support
None : None,
None: none,
None: none,
None : none, none

E. W. Godofsky, Vertex Pharma: Investigator and Speaker's Bureau, Research support and Speaker honorarium
Merck: Investigator, Research support
Roche: Investigator and Speaker's Bureau, Research support and Speaker honorarium
Gilead Pharm: Investigator, Research grant
Idenix Pharm: Investigator, Research support
BMS: Investigator, Research support
Boeringer Ingelheim: Investigator, Research support
Janssen: Investigator, Research support
Pharmasette: Investigator, Research support
Abbott: Investigator, Research support

R. T. Chung, Gilead: Investigator, Research grant
Roche Genentech: Grant Investigator, Research grant
Pfizer: Investigator, Research grant
Merck: Investigator, Research grant
NIH: Grant Investigator, Grant recipient

D. Bhattacharya, Vertex: Investigator, Research support

D. Wyles, Vertex Pharmaceuticals: Investigator, Research support
Merck: Investigator, Research support
Bristol-Myers Squibb: Consultant, Consulting fee
Gilead Sciences: Investigator, Research support
Janssen: Scientific Advisor, Consulting fee

See more of: Interactive Session

Findings in the abstracts are embargoed until 12:01 a.m. PST, Oct. 17th with the exception of research findings presented at the IDWeek press conferences.